Subscribe To
Solid power, inc. (sldp) stock alert: robbins llp is investigating solid power, inc.
SAN DIEGO, Dec. 11, 2022 (GLOBE NEWSWIRE) — Shareholder rights law firm Robbins LLP is investigating Solid Power, Inc. (NASDAQ: SLDP) to determine w...
December 12, 2022, 4:51 am
Neogenomics, inc. (neo) shareholder notice: robbins llp reminds investors of class action against neogenomics, inc.
SAN DIEGO, Dec. 11, 2022 (GLOBE NEWSWIRE) — The Class: Robbins LLP reminds investors that a shareholder filed a class action on behalf of all invest...
December 12, 2022, 4:20 am
Iris energy limited (iren) shareholder alert: robbins llp reminds investors of class action against iris energy limited
SAN DIEGO, Dec. 11, 2022 (GLOBE NEWSWIRE) — The Class: Robbins LLP reminds investors that a shareholder filed a class action on behalf of all person...
December 12, 2022, 4:17 am
F45 training holdings, inc. (fxlv) shareholder alert: robbins llp reminds investors of class action against f45 training holdings, inc.
SAN DIEGO, Dec. 11, 2022 (GLOBE NEWSWIRE) — The Class: Robbins LLP reminds investors that a shareholder filed a class action on behalf of all person...
December 12, 2022, 4:11 am
Mercedes-benz vans plans first electric-only plant in jawor
Mercedes-Benz Vans will build its first electric-only vans plant in Jawor, Poland, pending approval of conditions including the sign-off of subsidies ...
December 12, 2022, 4:01 am
Agios presents updated pyrukynd® (mitapivat) long-term extension data demonstrating sustained clinical benefits in adults with pyruvate kinase (pk) deficiency at 64th ash annual meeting and exposition
– Data Suggest Long-term Treatment with PYRUKYND® in Adults with PK Deficiency is Associated with Improvements in Hemoglobin, Iron Overload, Transf...
December 12, 2022, 12:00 am
The wall street journal: ukraine hits hotel housing russian military members
Footage of the Ukrainian artillery strike against a hotel in the Russian-occupied city of Melitopol showed dead and wounded Russian soldiers Read Full...
December 11, 2022, 11:46 pm
Igm biosciences presents data from t cell engager portfolio for hematologic malignancies at 2022 american society of hematology annual meeting
First Preclinical Data for IGM-2644 and IGM-2537 Featured in Poster Presentations MOUNTAIN VIEW, Calif., Dec. 11, 2022 (GLOBE NEWSWIRE) — IGM Biosci...
December 11, 2022, 3:00 pm
Agios presents updated pyrukynd® (mitapivat) data highlighting long-term safety profile and durable improvement in hemoglobin and markers of hemolysis and ineffective erythropoiesis in non-transfusion
– Actively Enrolling Phase 3 ENERGIZE and ENERGIZE-T Studies Evaluating PYRUKYND® in Adults with Non-transfusion-dependent and Transfusion-dependen...
December 10, 2022, 11:30 pm
Agios presents updated pyrukynd® (mitapivat) data highlighting long-term safety profile and durable improvement in hemoglobin and markers of hemolysis and ineffective erythropoiesis in non-transfusion
– Actively Enrolling Phase 3 ENERGIZE and ENERGIZE-T Studies Evaluating PYRUKYND® in Adults with Non-transfusion-dependent and Transfusion-dependen...
December 10, 2022, 11:30 pm
Agios presents updated pyrukynd® (mitapivat) data highlighting long-term safety profile and durable improvement in hemoglobin and markers of hemolysis and ineffective erythropoiesis in non-transfusion
– Actively Enrolling Phase 3 ENERGIZE and ENERGIZE-T Studies Evaluating PYRUKYND® in Adults with Non-transfusion-dependent and Transfusion-dependen...
December 10, 2022, 11:30 pm
Agios presents updated pyrukynd® (mitapivat) data highlighting long-term safety profile and durable improvement in hemoglobin and markers of hemolysis and ineffective erythropoiesis in non-transfusion
– Actively Enrolling Phase 3 ENERGIZE and ENERGIZE-T Studies Evaluating PYRUKYND® in Adults with Non-transfusion-dependent and Transfusion-dependen...
December 10, 2022, 11:30 pm
Agios presents updated pyrukynd® (mitapivat) data highlighting long-term safety profile and durable improvement in hemoglobin and markers of hemolysis and ineffective erythropoiesis in non-transfusion
– Actively Enrolling Phase 3 ENERGIZE and ENERGIZE-T Studies Evaluating PYRUKYND® in Adults with Non-transfusion-dependent and Transfusion-dependen...
December 10, 2022, 11:30 pm
Agios presents updated pyrukynd® (mitapivat) data highlighting long-term safety profile and durable improvement in hemoglobin and markers of hemolysis and ineffective erythropoiesis in non-transfusion
– Actively Enrolling Phase 3 ENERGIZE and ENERGIZE-T Studies Evaluating PYRUKYND® in Adults with Non-transfusion-dependent and Transfusion-dependen...
December 10, 2022, 11:30 pm
Agios presents updated pyrukynd® (mitapivat) data highlighting long-term safety profile and durable improvement in hemoglobin and markers of hemolysis and ineffective erythropoiesis in non-transfusion
– Actively Enrolling Phase 3 ENERGIZE and ENERGIZE-T Studies Evaluating PYRUKYND® in Adults with Non-transfusion-dependent and Transfusion-dependen...
December 10, 2022, 11:30 pm
Agios presents updated pyrukynd® (mitapivat) data highlighting long-term safety profile and durable improvement in hemoglobin and markers of hemolysis and ineffective erythropoiesis in non-transfusion
– Actively Enrolling Phase 3 ENERGIZE and ENERGIZE-T Studies Evaluating PYRUKYND® in Adults with Non-transfusion-dependent and Transfusion-dependen...
December 10, 2022, 11:30 pm
Agios presents updated pyrukynd® (mitapivat) data highlighting long-term safety profile and durable improvement in hemoglobin and markers of hemolysis and ineffective erythropoiesis in non-transfusion
– Actively Enrolling Phase 3 ENERGIZE and ENERGIZE-T Studies Evaluating PYRUKYND® in Adults with Non-transfusion-dependent and Transfusion-dependen...
December 10, 2022, 11:30 pm
Agios presents updated pyrukynd® (mitapivat) data highlighting long-term safety profile and durable improvement in hemoglobin and markers of hemolysis and ineffective erythropoiesis in non-transfusion
– Actively Enrolling Phase 3 ENERGIZE and ENERGIZE-T Studies Evaluating PYRUKYND® in Adults with Non-transfusion-dependent and Transfusion-dependen...
December 10, 2022, 11:30 pm
Agios presents updated pyrukynd® (mitapivat) data highlighting long-term safety profile and durable improvement in hemoglobin and markers of hemolysis and ineffective erythropoiesis in non-transfusion
– Actively Enrolling Phase 3 ENERGIZE and ENERGIZE-T Studies Evaluating PYRUKYND® in Adults with Non-transfusion-dependent and Transfusion-dependen...
December 10, 2022, 11:30 pm
Agios presents updated pyrukynd® (mitapivat) data highlighting long-term safety profile and durable improvement in hemoglobin and markers of hemolysis and ineffective erythropoiesis in non-transfusion
– Actively Enrolling Phase 3 ENERGIZE and ENERGIZE-T Studies Evaluating PYRUKYND® in Adults with Non-transfusion-dependent and Transfusion-dependen...
December 10, 2022, 11:30 pm